Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387790 · ClinicalTrials.gov registry record · Phase 2
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00387790: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00387790 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387790, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving motexafin gadolinium together with radiation therapy works in treating young patients with pontine glioma. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as motexafin gadolinium, may make tumor cells more sensitive to radiation therapy. Giving motexafin gadolinium together with radiation therapy may kill more tumor cells.
Interventions
- RADIATION 3-dimensional conformal radiation therapy
- DRUG motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387790
The ClinicalTrials.gov registry entry for NCT00387790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3-dimensional conformal radiation therapy is the first listed.
NCT00387790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387790 about?
NCT00387790 is a clinical study titled "Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma". This phase II trial is studying how well giving motexafin gadolinium together with radiation therapy works in treating young patients with pontine glioma. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as motexafin gadolinium, may make tumor cells more sensitive to radiat...
What is the current status of trial NCT00387790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-06. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00387790?
The interventions under investigation include: 3-dimensional conformal radiation therapy (RADIATION), motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00387790?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.